Stay updated with breaking news from Andreas Reif. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Intranasal esketamine (Spravato, Janssen) is superior to extended-release quetiapine (Seroquel, AstraZeneca) for treatment-resistant depression, results of a multicenter, head-to-head phase 3 trial show.
Esketamine has showcased promising results in a major clinical trial, proving more effective than standard treatments for treatment-resistant depression. Treatment-resistant depression (TRD) is a particularly challenging form of major depressive disorder. As Albino Oliveira-Maia, head of the Cham
A nasal spray containing a ketamine derivative appears to beat one of the standard drugs used for people with difficult-to-treat depression, a new clinical trial has found.
THURSDAY, Oct. 5, 2023 (HealthDay News) -- For patients with treatment-resistant depression, esketamine nasal spray is superior to extended-release quetiapine with respect to remission at week 8, according to a
A major clinical trial shows that the drug, esketamine, one of the two main forms of ketamine, outperforms one of the standard treatments for treatment-resistant major depression.